Acute and chronic kidney disease encompasses a complex set of diseases that can both
lead to, and result from, cancer. In particular, kidney disease can arise from the use of …

Preliminary evidence of safety and tolerability of atezolizu... : Hepatology Preliminary
evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with …

Photodynamic therapy (PDT) works through photoactivation of a specific photosensitizer
(PS) in a tumor in the presence of oxygen. PDT is widely applied in oncology to treat various …

Cancer is the second leading cause of death in people with chronic kidney disease (CKD)
after cardiovascular disease. The incidence of CKD in patients with cancer is higher than in …

Conventional chemotherapies remain the mainstay of treatment for many malignancies.
Kidney complications of these therapies are not infrequent and may have serious …

Cytochrome P450 3A4 (CYP3A4), one of the most important members of the cytochrome
P450 subfamily, is a crucial catalyst in the metabolism of numerous drugs. As it catalyzes …

Albumin, as the most abundant plasma protein, plays an integral role in the transport of a
variety of exogenous and endogenous ligands in the bloodstream and extravascular …

The prevalence of CKD may be higher in patients with cancer than in those without due to
the addition of cancer-specific risk factors to those already present for CKD. In this review …

Anaplastic lymphoma kinase (ALK) inhibitors are important treatment options for non-small-
cell lung cancer (NSCLC), associated with ALK gene rearrangement. Patients with ALK …

Protein-based cancer therapies are considered an alternative to conventional anticancer
regimens, providing multifunctional properties while showing low toxicity. However, its …